March 14, 2002(1)

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com



FOR IMMEDIATE RELEASE

ZOLL Medical Corporation Updates Progress on AED

Burlington, MA, March 14, 2002  Thursday, March 14, 2002 – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices which provide pacing and defibrillation, reiterated that 510k clearance of the new ZOLL AED Plus product is still expected to be received before the end of March.

Richard A. Packer, President and Chief Executive Officer of ZOLL stated, “We have been in continual communication with the FDA on the status of our application. Since the major data was submitted in early January, the process has been typical, except that the pace has been slower than anticipated. Based on our latest contact with the FDA, we continue to be optimistic that the clearance will be received in the next two weeks. However, given that we are late in the quarter, we believe that we will not have PAD revenue this quarter.”

Mr. Packer further noted, “We continue to receive strong interest from potential customers and we are very excited about our prospects for the second half of fiscal 2002. Upon receipt of FDA approval, we will immediately begin taking orders in the United States and additional international markets. We expect the product will be finalized and that shipments will begin during our third fiscal quarter. Our estimates for shipments during the second half of fiscal 2002 are now in the range of $5M - $7M.”

Addressing the current quarter’s business, Mr. Packer added, “Although we still have a lot of business to close in the remainder of our quarter, as is our usual practice, the North American market seems to be strong in both the Hospital and EMS markets. Acceptance of the new
M Series CCT product continues to be good. Internationally we have experienced some weakness in the European market. In total we believe that the non-PAD business will be on track for the quarter but it is possible that we will not generate enough orders to again fill the gap left by not shipping the AED.”

A conference call has been scheduled to discuss these items, other progress in the public access defibrillation (PAD) market, and our recent announcement regarding our agreement with Broadlane, on March 15, 2002. The conference call will be held at 9:00 a.m. Eastern Standard Time.

If you are interested in listening to the conference call, please dial 888-848-6503 and reference the pass code “ZOLL”. The conference call leader will be Mr. Richard Packer, President and CEO of ZOLL.

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation—pacing and defibrillation—these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software, which automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands, Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit the ZOLL web site at www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of the Company's business, the intent, belief or current expectations of the Company, its directors or its officers, primarily with respect to the Company's business model and future operating performance of the Company, including expectations regarding results in future periods, operating performance, contributions to results from the Company’s new Public Access Defibrillation product, the payoff that may be realized from investments and the Company’s future profitability, its ability to establish a new sales force in foreign markets, its expectations regarding future purchasing activity, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-Q filed on February 13, 2002 as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus and M Series CCT, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital market, the potential disruption in the transportation industry on the Company’s supply chain and product distribution channels, and the desire or ability of other parties to purchase the Company's products.

##